发明名称 Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers
摘要 In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.
申请公布号 US9532949(B2) 申请公布日期 2017.01.03
申请号 US201214233527 申请日期 2012.07.18
申请人 STC.UNM 发明人 Zeineldin Reema
分类号 A61K9/51;A61K9/127;A61K31/704;A61K9/00 主分类号 A61K9/51
代理机构 Schwegman Lundberg & Woessner, P.A. 代理人 Schwegman Lundberg & Woessner, P.A.
主权项 1. A method of treating a subject who suffers from a cancer, the method comprising intraperitoneally administering to the subject a pharmaceutically effective amount of a nanocarrier composition, comprising a plurality of porous nanoparticulates that are loaded with one or more pharmaceutically active anticancer agents and are encapsulated by and support a lipid bilayer which is disrupted upon contact with a reactive oxygen species, wherein the lipid bilayer comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).
地址 Albuquerque NM US